ATE370958T1 - Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung - Google Patents

Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung

Info

Publication number: ATE370958T1
Authority: AT; Austria
Prior art keywords: phosphonooxy; pharmaceutical use; quinazoline derivatives; quinazoline; derivatives
Prior art date: 2002-12-24

Application number

AT03782672T

Other languages

English (en)

Inventor

Nicola Murdoch Heron

Frederic Henri Jung

Georges Rene Pasquet

Andrew A Mortlock

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-24

Filing date

2003-12-22

Publication date

2007-09-15

2003-12-22 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2007-09-15 Application granted granted Critical

2007-09-15 Publication of ATE370958T1 publication Critical patent/ATE370958T1/de

Links

PEPCBVCPSRHOBI-UHFFFAOYSA-N quinazolin-2-yl dihydrogen phosphate Chemical class C1=CC=CC2=NC(OP(O)(=O)O)=NC=C21 PEPCBVCPSRHOBI-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT03782672T 2002-12-24 2003-12-22 Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung ATE370958T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02293238		2002-12-24
EP03291315		2003-06-02

Publications (1)

Publication Number	Publication Date
ATE370958T1 true ATE370958T1 (de)	2007-09-15

Family

ID=32683824

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT07009390T ATE438644T1 (de)	2002-12-24	2003-12-22	Chinazolinderivate
AT03782672T ATE370958T1 (de)	2002-12-24	2003-12-22	Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT07009390T ATE438644T1 (de)	2002-12-24	2003-12-22	Chinazolinderivate

Country Status (29)

Country	Link
US (4)	US7528121B2 (de)
EP (2)	EP1578755B1 (de)
JP (3)	JP4422102B2 (de)
KR (1)	KR101010299B1 (de)
AR (2)	AR042668A1 (de)
AT (2)	ATE438644T1 (de)
AU (1)	AU2003290313B2 (de)
BR (1)	BRPI0317717B8 (de)
CA (1)	CA2511613C (de)
CL (1)	CL2003002731A1 (de)
CY (2)	CY1107775T1 (de)
DE (2)	DE60328735D1 (de)
DK (2)	DK1578755T3 (de)
ES (2)	ES2290529T3 (de)
IL (2)	IL169112A (de)
IS (2)	IS2504B (de)
MX (1)	MXPA05006918A (de)
MY (2)	MY147761A (de)
NO (2)	NO335193B1 (de)
NZ (1)	NZ540698A (de)
PL (2)	PL223998B1 (de)
PT (2)	PT1847539E (de)
RU (3)	RU2350611C1 (de)
SA (1)	SA04240504B1 (de)
SI (2)	SI1847539T1 (de)
TW (2)	TWI336327B (de)
UA (1)	UA83814C2 (de)
UY (1)	UY28149A1 (de)
WO (1)	WO2004058781A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003055491A1 (en) *	2001-12-24	2003-07-10	Astrazeneca Ab	Substituted quinazoline derivatives as inhibitors of aurora kinases
SI1847539T1 (sl)	2002-12-24	2010-01-29	Astrazeneca Ab	Kinazolinski derivati
MXPA05006920A (es) *	2002-12-24	2006-02-10	Astrazeneca Ab	Compuestos de quinazolina.
KR20060003351A (ko) *	2003-04-16	2006-01-10	아스트라제네카 아베	화합물
CA2526285A1 (en) *	2003-05-15	2004-12-23	Arqule, Inc.	Inhibitors of p38 and methods of using the same
ATE401080T1 (de) *	2003-06-02	2008-08-15	Astrazeneca Ab	(3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
EP1694686A1 (de)	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinaseinhibitoren
WO2006023931A2 (en)	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
BRPI0516093A (pt) *	2004-10-12	2008-08-19	Astrazeneca Ab	derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
US20090036474A1 (en) *	2004-10-12	2009-02-05	Patrick Ple	Quinazoline derivatives for use against cancer
EP1812439B2 (de)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinaseinhibitoren
EP2258704A1 (de) *	2004-10-19	2010-12-08	ArQule, Inc.	Synthese aus Imidazooxazol- und Imidazothiazol-hemmern der P38-map-kinase
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
UY30183A1 (es)	2006-03-02	2007-10-31	Astrazeneca Ab	Derivados de quinolina
WO2007123892A2 (en) *	2006-04-17	2007-11-01	Arqule Inc.	Raf inhibitors and their uses
GB0609621D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal
GB0609617D0 (en)	2006-05-16	2006-06-21	Astrazeneca Ab	Process & intermediate
GB0609619D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Combination
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
WO2009111028A1 (en) *	2008-03-04	2009-09-11	Vitae Pharmaceuticals, Inc.	Aurora kinase inhibitors
WO2009114703A2 (en) *	2008-03-12	2009-09-17	Fox Chase Cancer Center	Combination therapy for the treatment of cancer
CN102014627B (zh)	2008-04-30	2014-10-29	国家卫生研究院	作为极光激酶抑制剂的稠合双环嘧啶化合物
MX2010013842A (es) *	2008-07-03	2011-01-14	Merck Patent Gmbh	Naftiridinonas como inhibidores de aurora cinasa.
EP2361254A1 (de) *	2008-12-05	2011-08-31	ArQule, Inc.	Raf-inhibitoren und anwendungen davon
BRPI0923504A2 (pt)	2008-12-11	2020-05-26	Axcentua Pharmaceuticals Ab	Formas cristalinas de genisteína.
US7863325B2 (en)	2008-12-11	2011-01-04	Axcentua Pharmaceuticals Ab	Crystalline genistein sodium salt dihydrate
RU2535032C2 (ru)	2008-12-22	2014-12-10	Милленниум Фармасьютикалз, Инк.	Сочетание ингибиторов аврора киназы и анти-cd 20 антител
US9604963B2 (en)	2011-03-04	2017-03-28	Glaxosmithkline Intellectual Property Development Limited	Amino-quinolines as kinase inhibitors
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh)	2012-09-13	2014-07-01	Glaxosmithkline Llc	作為激酶抑制劑之胺基－喹啉類
EP2956138B1 (de)	2013-02-15	2022-06-22	Kala Pharmaceuticals, Inc.	Therapeutische verbindungen und verwendungen davon
MX368903B (es)	2013-02-20	2019-10-21	Kala Pharmaceuticals Inc	Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CA2902132C (en)	2013-02-21	2020-09-22	Glaxosmithkline Intellectual Property Development Limited	Quinazolines as kinase inhibitors
RS60093B1 (sr) *	2013-09-16	2020-05-29	Astrazeneca Ab	Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
US9458169B2 (en)	2013-11-01	2016-10-04	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
EP3076963A4 (de)	2013-12-06	2017-09-13	Millennium Pharmaceuticals, Inc.	Kombination aus aurorakinaseinhibitoren und anti-cd30-antikörpern
WO2017015316A1 (en)	2015-07-21	2017-01-26	Millennium Pharmaceuticals, Inc.	Administration of aurora kinase inhibitor and chemotherapeutic agents
AU2017324713B2 (en)	2016-09-08	2020-08-13	KALA BIO, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en)	2016-09-08	2019-07-02	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (de)	2016-09-08	2020-05-13	Kala Pharmaceuticals, Inc.	Kristalline formen von therapeutischen verbindungen und verwendungen davon
KR20240151869A (ko)	2017-09-08	2024-10-18	더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티	Enpp1 저해제 및 암의 치료용의 이의 용도
WO2019195658A1 (en)	2018-04-05	2019-10-10	Dana-Farber Cancer Institute, Inc.	Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es)	2018-09-09	2020-03-12	Fundacio Privada Institut De Recerca De La Sida - Caixa	Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en)	2019-08-26	2022-09-29	Dana-Farber Cancer Institute, Inc.	Use of heparin to promote type 1 interferon signaling
WO2021094379A1 (en)	2019-11-12	2021-05-20	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) *	2019-12-11	2022-05-17	苏州美诺医药科技有限公司	新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en)	2021-03-10	2022-09-15	Astrazeneca Ab	Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL89029A (en)	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
SG64322A1 (en)	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1995033724A1 (en)	1994-06-09	1995-12-14	Glaxo Group Limited	Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (de)	1994-11-12	1997-12-01	Zeneca Ltd
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
KR100459052B1 (ko)	1995-12-18	2005-01-15	서젠, 인크.	Aur-1및(또는)aur-2관련질병의진단및치료
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
US6716575B2 (en)	1995-12-18	2004-04-06	Sugen, Inc.	Diagnosis and treatment of AUR1 and/or AUR2 related disorders
DE69720965T2 (de)	1996-02-13	2004-02-05	Astrazeneca Ab	Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en)	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
US7262201B1 (en) *	1998-10-08	2007-08-28	Astrazeneca Ab	Quinazoline derivatives
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
CA2384291A1 (en)	1999-09-21	2001-03-29	Astrazeneca Ab	Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
AU2001258628A1 (en)	2000-05-31	2001-12-11	Astrazeneca Ab	Indole derivatives with vascular damaging activity
IL153246A0 (en)	2000-06-28	2003-07-06	Astrazeneca Ab	Substituted quinazoline derivatives and their use as inhibitors
MXPA02012905A (es)	2000-07-07	2004-07-30	Angiogene Pharm Ltd	Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es)	2000-07-07	2004-07-30	Angiogene Pharm Ltd	Derivados de colquinol como inhibidores de angiogenesis.
PT1315715E (pt) *	2000-08-18	2008-10-30	Millennium Pharm Inc	Derivados de quianazolina utilizados como inibidores de quinase
US6610677B2 (en)	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7132427B2 (en) *	2001-06-21	2006-11-07	Ariad Pharmaceuticals, Inc.	Quinazolines and uses thereof
GB0124299D0 (en) *	2001-10-10	2001-11-28	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
WO2003055491A1 (en) *	2001-12-24	2003-07-10	Astrazeneca Ab	Substituted quinazoline derivatives as inhibitors of aurora kinases
MXPA05006920A (es) *	2002-12-24	2006-02-10	Astrazeneca Ab	Compuestos de quinazolina.
SI1847539T1 (sl) *	2002-12-24	2010-01-29	Astrazeneca Ab	Kinazolinski derivati
KR20060003351A (ko) *	2003-04-16	2006-01-10	아스트라제네카 아베	화합물

2003
- 2003-12-22 SI SI200331673T patent/SI1847539T1/sl unknown
- 2003-12-22 AU AU2003290313A patent/AU2003290313B2/en not_active Expired
- 2003-12-22 RU RU2007121850/04A patent/RU2350611C1/ru active
- 2003-12-22 PL PL412704A patent/PL223998B1/pl unknown
- 2003-12-22 WO PCT/GB2003/005613 patent/WO2004058781A1/en not_active Ceased
- 2003-12-22 PL PL377680A patent/PL221490B1/pl unknown
- 2003-12-22 DK DK03782672T patent/DK1578755T3/da active
- 2003-12-22 MX MXPA05006918A patent/MXPA05006918A/es active IP Right Grant
- 2003-12-22 ES ES03782672T patent/ES2290529T3/es not_active Expired - Lifetime
- 2003-12-22 SI SI200330965T patent/SI1578755T1/sl unknown
- 2003-12-22 AT AT07009390T patent/ATE438644T1/de active
- 2003-12-22 PT PT07009390T patent/PT1847539E/pt unknown
- 2003-12-22 KR KR1020057012015A patent/KR101010299B1/ko not_active Expired - Lifetime
- 2003-12-22 MY MYPI20071321A patent/MY147761A/en unknown
- 2003-12-22 NZ NZ540698A patent/NZ540698A/en not_active IP Right Cessation
- 2003-12-22 CL CL200302731A patent/CL2003002731A1/es unknown
- 2003-12-22 US US10/539,220 patent/US7528121B2/en active Active
- 2003-12-22 EP EP03782672A patent/EP1578755B1/de not_active Expired - Lifetime
- 2003-12-22 MY MYPI20034944A patent/MY136174A/en unknown
- 2003-12-22 DE DE60328735T patent/DE60328735D1/de not_active Expired - Lifetime
- 2003-12-22 AT AT03782672T patent/ATE370958T1/de active
- 2003-12-22 CA CA2511613A patent/CA2511613C/en not_active Expired - Lifetime
- 2003-12-22 ES ES07009390T patent/ES2329623T3/es not_active Expired - Lifetime
- 2003-12-22 BR BRPI0317717A patent/BRPI0317717B8/pt not_active IP Right Cessation
- 2003-12-22 UA UAA200507294A patent/UA83814C2/ru unknown
- 2003-12-22 RU RU2005123485/04A patent/RU2357971C2/ru active
- 2003-12-22 DE DE60315892T patent/DE60315892T2/de not_active Expired - Lifetime
- 2003-12-22 JP JP2005509716A patent/JP4422102B2/ja not_active Expired - Lifetime
- 2003-12-22 EP EP07009390A patent/EP1847539B1/de not_active Expired - Lifetime
- 2003-12-22 PT PT03782672T patent/PT1578755E/pt unknown
- 2003-12-22 DK DK07009390T patent/DK1847539T3/da active
- 2003-12-23 UY UY28149A patent/UY28149A1/es not_active Application Discontinuation
- 2003-12-23 TW TW092136601A patent/TWI336327B/zh not_active IP Right Cessation
- 2003-12-23 AR ARP030104824A patent/AR042668A1/es active IP Right Grant
- 2003-12-23 TW TW099134275A patent/TWI393710B/zh not_active IP Right Cessation
2004
- 2004-02-18 SA SA04240504A patent/SA04240504B1/ar unknown
2005
- 2005-06-09 IL IL169112A patent/IL169112A/en active IP Right Grant
- 2005-06-13 NO NO20052855A patent/NO335193B1/no not_active IP Right Cessation
- 2005-07-20 IS IS7948A patent/IS2504B/is unknown
2007
- 2007-05-16 AR ARP070102117A patent/AR057753A2/es not_active Application Discontinuation
- 2007-06-13 RU RU2007121850/04K patent/RU2007121850A/ru unknown
- 2007-06-28 JP JP2007169891A patent/JP4906608B2/ja not_active Expired - Lifetime
- 2007-08-09 IL IL185176A patent/IL185176A/en active IP Right Grant
- 2007-10-24 CY CY20071101369T patent/CY1107775T1/el unknown
2008
- 2008-02-13 IS IS8714A patent/IS2884B/is unknown
- 2008-10-15 JP JP2008265949A patent/JP4503090B2/ja not_active Expired - Lifetime
2009
- 2009-04-28 US US12/431,165 patent/US8268841B2/en not_active Expired - Lifetime
- 2009-10-13 CY CY20091101054T patent/CY1109479T1/el unknown
2012
- 2012-08-21 US US13/590,662 patent/US9018191B2/en not_active Expired - Lifetime
2013
- 2013-11-01 NO NO20131444A patent/NO335446B1/no not_active IP Right Cessation
2015
- 2015-03-18 US US14/661,657 patent/US9567358B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20100069412A1 (en)	2010-03-18
EP1847539A1 (de)	2007-10-24
EP1578755A1 (de)	2005-09-28
DE60328735D1 (de)	2009-09-17
PL221490B1 (pl)	2016-04-29
IL185176A0 (en)	2007-12-03
BRPI0317717B8 (pt)	2021-05-25
IL169112A (en)	2010-12-30
IL185176A (en)	2011-10-31
SI1847539T1 (sl)	2010-01-29
EP1847539B1 (de)	2009-08-05
CY1109479T1 (el)	2014-08-13
JP2006512418A (ja)	2006-04-13
UY28149A1 (es)	2004-07-30
ATE438644T1 (de)	2009-08-15
IS7948A (is)	2005-07-20
JP2009046514A (ja)	2009-03-05
DK1578755T3 (da)	2007-11-12
MXPA05006918A (es)	2005-08-18
NO20052855D0 (no)	2005-06-13
NO20052855L (no)	2005-08-03
RU2007121850A (ru)	2008-12-20
JP4422102B2 (ja)	2010-02-24
PL377680A1 (pl)	2006-02-06
IL169112A0 (en)	2009-02-11
UA83814C2 (ru)	2008-08-26
SA04240504B1 (ar)	2008-04-01
MY147761A (en)	2013-01-31
TW201102369A (en)	2011-01-16
DE60315892D1 (de)	2007-10-04
ES2329623T3 (es)	2009-11-27
HK1111417A1 (en)	2008-08-08
CY1107775T1 (el)	2013-06-19
PL223998B1 (pl)	2016-11-30
NZ540698A (en)	2008-05-30
DK1847539T3 (da)	2009-11-09
RU2350611C1 (ru)	2009-03-27
IS2884B (is)	2014-06-15
US8268841B2 (en)	2012-09-18
KR101010299B1 (ko)	2011-01-25
CL2003002731A1 (es)	2005-01-07
US7528121B2 (en)	2009-05-05
PT1578755E (pt)	2007-10-19
JP2007326862A (ja)	2007-12-20
JP4906608B2 (ja)	2012-03-28
CA2511613C (en)	2012-10-02
SI1578755T1 (sl)	2007-12-31
PT1847539E (pt)	2009-10-06
AU2003290313A1 (en)	2004-07-22
TWI336327B (en)	2011-01-21
IS8714A (is)	2008-02-13
NO335193B1 (no)	2014-10-20
TWI393710B (zh)	2013-04-21
DE60315892T2 (de)	2008-08-14
MY136174A (en)	2008-08-29
BR0317717A (pt)	2005-11-22
US20140162984A1 (en)	2014-06-12
RU2357971C2 (ru)	2009-06-10
US9567358B2 (en)	2017-02-14
NO20131444L (no)	2005-08-03
SA04240504A (ar)	2005-12-03
TW200510342A (en)	2005-03-16
AU2003290313B2 (en)	2007-05-10
US20150307534A1 (en)	2015-10-29
JP4503090B2 (ja)	2010-07-14
RU2005123485A (ru)	2006-03-10
US20060116357A1 (en)	2006-06-01
HK1080481A1 (en)	2006-04-28
EP1578755B1 (de)	2007-08-22
PL412704A1 (pl)	2015-10-12
AR042668A1 (es)	2005-06-29
AR057753A2 (es)	2007-12-19
NO335446B1 (no)	2014-12-15
KR20050088333A (ko)	2005-09-05
CA2511613A1 (en)	2004-07-15
WO2004058781A1 (en)	2004-07-15
BRPI0317717B1 (pt)	2017-12-19
IS2504B (is)	2009-04-15
ES2290529T3 (es)	2008-02-16
US9018191B2 (en)	2015-04-28

Legal Events

Date

Code

Title

Description

2007-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1578755

Country of ref document: EP

Publication	Publication Date	Title
DE60315892D1 (de)	2007-10-04	Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
ATE381335T1 (de)	2008-01-15	2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
ATE479437T1 (de)	2010-09-15	Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DE60208351D1 (de)	2006-02-02	Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de)	2009-02-12	Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de)	2010-10-21	Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60201859D1 (de)	2004-12-16	Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
DE60314600D1 (de)	2007-08-09	O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
DE60325761D1 (de)	2009-02-26	Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
EE200300311A (et)	2003-10-15	Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
ATE430133T1 (de)	2009-05-15	N-hydroxyamid derivate und ihre verwendung
DE60323754D1 (de)	2008-11-06	Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
ATE502035T1 (de)	2011-04-15	2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
DE50206476D1 (de)	2006-05-24	Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
DE60311598D1 (de)	2007-03-22	Naphthyridin-derivate und ihre verwendung als fungizide
ATE396994T1 (de)	2008-06-15	3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE459608T1 (de)	2010-03-15	Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE60336999D1 (de)	2011-06-16	Melatonin enthaltende pharmazeutische formulierung
DE602004022169D1 (de)	2009-09-03	Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE60238856D1 (de)	2011-02-17	Anthranilsäureamide und ihre pharmazeutische verwendung
EE200300454A (et)	2003-12-15	Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine
DE60316134D1 (de)	2007-10-18	Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
ZA200504997B (en)	2007-11-28	Phosphonooxy quinazolin derivatives and their pharmaceutical use
ATE362916T1 (de)	2007-06-15	Substituierte propan- 1,3-diamin-derivate und ihre pharmazeutische verwendung
DE60317719D1 (de)	2008-01-03	Kosmetische und pharmazeutische zusammensetzungen mit lycopin